CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Posted: 08/02/2016
Author:
Nicole Lou Reporter, MedPage Today/CRTonline.org
Adult Congenital Heart Disease Valve & Structural News

The CoreValve Evolut R System has been cleared by European regulators for treating intermediate-risk patients, making it the first transcatheter aortic valve replacement (TAVR, also known as TAVI) device to win an expanded indication for this population.
1-3 of 4071 results
1 2 3 4 5 Next »

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

Jan 14, 2025 by
Nathan Gray, CRTonline.org

While multiple advancements in left atrial appendage occlusion (LAAO) devices have emerged for stroke prevention and arrhythmia therapy, several unanswered questions remain, specifically regarding the patient and device selection and the management of complications, according to a new review.

Non-Trial SAVR Patients Have Comparable Mortality, Fewer Strokes Than Trial Patients From PARTNER 3 and Evolut Low Risk: Cross-Sectional Study

Jan 06, 2025 by
Bailey G. Salimes, CRTonline.org

Low-risk, trial-like patients undergoing surgical aortic valve replacement (SAVR) during the trial enrollment period have similar 30-day rates of mortality, but lower rates of stroke, compared with patients in the SAVR arm of the PARTNER 3 and Evolut Low Risk trials, a cross-sectional analysis shows.

Redo TAVR With SAPIEN 3 Associated With Downsizing, Under-Expansion “Complexities”: Patient Analysis

Dec 23, 2024 by
Nathan Gray, CRTonline.org

Redo transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 (S3) valve presents challenges, according to a new analysis of patient data that also shows downsizing is frequent, and under-expansion may lead to suboptimal hemodynamics.

1-3 of 4071 results
1 2 3 4 5 Next »

Most Viewed Pages

Hypertension While Lying Down Carries Greater CVD Risks vs Hypertension While Seated: Cohort Study

IVUS for FPA With DCB Shows Promising Clinical Outcomes in Patients With Complex FPA Lesions: IVUS-DCB Subgroup Analysis

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

AI Assists in Predicting Incident Hypertension, Adverse Outcomes: Cohort Study

From ST-Segment Elevation MI to Occlusion MI: The New Paradigm Shift in Acute Myocardial Infarction

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Despite Recent Advances in LAAO, Questions Remain Over Patient, Device Selection: State-of-the-Art Review

Non-Trial SAVR Patients Have Comparable Mortality, Fewer Strokes Than Trial Patients From PARTNER 3 and Evolut Low Risk: Cross-Sectional Study

Redo TAVR With SAPIEN 3 Associated With Downsizing, Under-Expansion “Complexities”: Patient Analysis

Most Viewed Pages

Explore the Site

Stay Connected